DocGo Stock Price, News & Analysis (NASDAQ:DCGO) $5.48 -0.08 (-1.44%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$5.47▼$5.7450-Day Range$5.13▼$6.7552-Week Range$4.88▼$10.82Volume1.04 million shsAverage Volume785,625 shsMarket Capitalization$569.35 millionP/E Ratio60.89Dividend YieldN/APrice Target$13.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media DocGo MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside148.2% Upside$13.60 Price TargetShort InterestHealthy10.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 7 Articles This WeekInsider TradingSelling Shares$148,793 Sold Last QuarterProj. Earnings Growth512.50%From $0.08 to $0.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.75 out of 5 starsMedical Sector78th out of 957 stocksHealth Services Industry3rd out of 12 stocks 3.5 Analyst's Opinion Consensus RatingDocGo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.60, DocGo has a forecasted upside of 148.2% from its current price of $5.48.Amount of Analyst CoverageDocGo has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.72% of the float of DocGo has been sold short.Short Interest Ratio / Days to CoverDocGo has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in DocGo has recently decreased by 5.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDocGo does not currently pay a dividend.Dividend GrowthDocGo does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCGO. Previous Next 2.5 News and Social Media Coverage News SentimentDocGo has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for DocGo this week, compared to 3 articles on an average week.Search Interest5 people have searched for DCGO on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DocGo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $148,793.00 in company stock.Percentage Held by Insiders13.78% of the stock of DocGo is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.14% of the stock of DocGo is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for DocGo are expected to grow by 512.50% in the coming year, from $0.08 to $0.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DocGo is 60.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.44.Price to Earnings Ratio vs. SectorThe P/E ratio of DocGo is 60.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.64.Price to Book Value per Share RatioDocGo has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DocGo Stock (NASDAQ:DCGO)DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices; testing; vaccinations; and event services, which include on-site healthcare support at sporting events and concerts. DocGo Inc. was incorporated in 2015 and is based in New York, New York.Read More DCGO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCGO Stock News HeadlinesDecember 6, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Potential Recovery for DocGo Inc. (DCGO) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action LawsuitDecember 4, 2023 | americanbankingnews.comShort Interest in DocGo Inc. (NASDAQ:DCGO) Decreases By 5.3%December 7, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!December 3, 2023 | barrons.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in DocGo Inc. with Losses In Excess of $100,000 to Contact the FirmNovember 30, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Henry Schein (HSIC), DocGo (DCGO)November 30, 2023 | seekingalpha.comDocGo: Growth Significantly Exceeded My ExpectationsNovember 30, 2023 | finance.yahoo.comDocGo Inc. (NASDAQ:DCGO) is largely controlled by institutional shareholders who own 59% of the companyNovember 29, 2023 | benzinga.comDocGo Stock (NASDAQ:DCGO), Analyst Ratings, Price Targets, PredictionsDecember 7, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!November 29, 2023 | americanbankingnews.comDocGo (NASDAQ:DCGO) Rating Reiterated by Stifel NicolausNovember 28, 2023 | benzinga.comDocGo Inc. investors: Please contact the Portnoy...November 28, 2023 | barrons.comDocGo Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More InformationNovember 27, 2023 | barrons.comDCGO Class Action Alert: Bronstein, Gewirtz & Grossman LLC Reminds DocGo Inc Investors with Substantial Losses to Contact the Firm!November 27, 2023 | markets.businessinsider.com7 Analysts Have This to Say About DocGoNovember 24, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Potential Recovery for DocGo Inc. (DCGO) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action LawsuitNovember 22, 2023 | benzinga.comDCGO Investors Have Opportunity to Lead DocGo Inc. Securities Fraud LawsuitNovember 22, 2023 | barrons.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in DocGo Inc. with Losses of $100,000 to Contact the FirmNovember 22, 2023 | barrons.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies DocGo Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - DCGONovember 20, 2023 | businesswire.comDCGO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DocGo Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!November 19, 2023 | barrons.comINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of DocGo Inc.(DCGO) of a Class Action Lawsuit and an Upcoming DeadlineNovember 18, 2023 | benzinga.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages DocGo Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DCGONovember 17, 2023 | barrons.comDocGo Shareholder AlertNovember 14, 2023 | benzinga.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DocGo Inc. (DCGO)November 14, 2023 | businesswire.comDCGO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DocGo Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!November 14, 2023 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DocGo Inc. (DCGO)November 14, 2023 | barrons.comINVESTOR ALERT: Potential Recovery for DocGo Inc. (DCGO) Investors Affected by Stock Drop -- Levi & Korsinsky Pursuing Class Action LawsuitNovember 12, 2023 | markets.businessinsider.comDocGo Ongoing Deadline AlertSee More Headlines Receive DCGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DocGo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Health services Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DCGO CUSIPN/A CIK1822359 Webwww.docgo.com Phone844-443-6246FaxN/AEmployees3,252Year FoundedN/APrice Target and Rating Average Stock Price Target$13.60 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+148.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.09 Trailing P/E Ratio60.89 Forward P/E Ratio68.50 P/E GrowthN/ANet Income$34.58 million Net Margins1.38% Pretax Margin0.40% Return on Equity3.11% Return on Assets2.20% Debt Debt-to-Equity Ratio0.01 Current Ratio2.36 Quick Ratio2.36 Sales & Book Value Annual Sales$533.83 million Price / Sales1.07 Cash Flow$0.42 per share Price / Cash Flow13.12 Book Value$2.72 per share Price / Book2.01Miscellaneous Outstanding Shares103,896,000Free Float89,579,000Market Cap$569.35 million OptionableNot Optionable Beta0.92 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Stan Vashovsky (Age 50)Co-Founder & Non-Executive Chairman Comp: $2.45MMr. Lee Bienstock (Age 39)Chief Executive Officer Comp: $1.24MMr. Ely D. Tendler (Age 55)General Counsel, Secretary & Director Mr. Norman Rosenberg (Age 53)Treasurer & CFO Mike ColeVice President of Investor RelationsMr. Stephen Sugrue (Age 51)Chief Compliance Officer Mr. Ben ShermanEVP of Corporate DevelopmentMs. Rosemarie MilanoVice President of Human ResourcesMr. Andre Oberholzer CPA (Age 65)Executive Vice President of Strategy Comp: $1.75MMr. Aaron SeversChief Product OfficerMore ExecutivesKey CompetitorsInnovAgeNASDAQ:INNVTango TherapeuticsNASDAQ:TNGXThe Pennant GroupNASDAQ:PNTGP3 Health PartnersNASDAQ:PIIITalkspaceNASDAQ:TALKView All CompetitorsInsiders & InstitutionsStephen SugrueSold 2,859 sharesTotal: $16,439.25 ($5.75/share)Deutsche Bank AGBought 4,918 shares on 11/24/2023Ownership: 0.042%Comerica BankBought 18,252 shares on 11/21/2023Ownership: 0.018%Wolverine Trading LLCBought 15,000 shares on 11/16/2023Ownership: 0.000%Integrated Wealth Concepts LLCBought 14,199 shares on 11/15/2023Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions DCGO Stock Analysis - Frequently Asked Questions Should I buy or sell DocGo stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DocGo in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DCGO shares. View DCGO analyst ratings or view top-rated stocks. What is DocGo's stock price target for 2024? 4 brokers have issued 1 year target prices for DocGo's shares. Their DCGO share price targets range from $12.00 to $16.00. On average, they expect the company's share price to reach $13.60 in the next year. This suggests a possible upside of 148.2% from the stock's current price. View analysts price targets for DCGO or view top-rated stocks among Wall Street analysts. How have DCGO shares performed in 2023? DocGo's stock was trading at $7.07 at the beginning of the year. Since then, DCGO stock has decreased by 22.5% and is now trading at $5.48. View the best growth stocks for 2023 here. Are investors shorting DocGo? DocGo saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 9,380,000 shares, a drop of 5.3% from the October 31st total of 9,900,000 shares. Based on an average trading volume of 1,040,000 shares, the short-interest ratio is currently 9.0 days. Currently, 10.7% of the company's stock are sold short. View DocGo's Short Interest. When is DocGo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024. View our DCGO earnings forecast. How were DocGo's earnings last quarter? DocGo Inc. (NASDAQ:DCGO) released its earnings results on Monday, November, 6th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by $0.02. The company earned $186.55 million during the quarter, compared to the consensus estimate of $145.64 million. DocGo had a trailing twelve-month return on equity of 3.11% and a net margin of 1.38%. What ETFs hold DocGo's stock? ETFs with the largest weight of DocGo (NASDAQ:DCGO) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC).iShares U.S. Healthcare Providers ETF (IHF). Who are DocGo's major shareholders? DocGo's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (4.59%), Emerald Advisers LLC (2.32%), WCM Investment Management LLC (2.15%), Punch & Associates Investment Management Inc. (1.98%), Emerald Mutual Fund Advisers Trust (1.84%) and Kennedy Capital Management LLC (1.80%). Insiders that own company stock include Adriaan Stephanus Oberholzer, Anthony Capone, Ely D Tendler, James M Travers, Lee Bienstock and Stephen Sugrue. View institutional ownership trends. How do I buy shares of DocGo? Shares of DCGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:DCGO) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DocGo Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.